Cargando…
SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is the most common pancreatic malignancy. Due to its wide heterogeneity, PDAC acts aggressively and responds poorly to most chemotherapies, causing an urgent need for the development of new therapeutic strategies. Cell lines have been used as the f...
Autores principales: | Liu, Enze, Zhang, Zhuang Zhuang, Cheng, Xiaolin, Liu, Xiaoqi, Cheng, Lijun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7119297/ https://www.ncbi.nlm.nih.gov/pubmed/32241274 http://dx.doi.org/10.1186/s12920-020-0681-6 |
Ejemplares similares
-
The use of Multidimensional Data to Identify the Molecular Biomarker for Pancreatic Ductal Adenocarcinoma
por: Zhuang, Liwei, et al.
Publicado: (2013) -
Prognostic Nomogram for Patients With Pancreatic Ductal Adenocarcinoma of Pancreatic Head After Pancreaticoduodenectomy
por: Zhuang, Hongkai, et al.
Publicado: (2021) -
Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma
por: Rebelo, Rita, et al.
Publicado: (2021) -
XDec-CHI reveals immunosuppressive interactions in pancreatic ductal adenocarcinoma
por: LaPlante, Emily L., et al.
Publicado: (2022) -
Key drug-targeting genes in pancreatic ductal adenocarcinoma
por: Sakharkar, Meena Kishore, et al.
Publicado: (2021)